Citations

Clear

634 citation(s) found for "Hall, A".

Testing a clinical staging model for bipolar disorder using longitudinal life chart data
Markt, Afra van der , Klumpers, Ursula M. H. , Draisma, Stasja , Dols, Annemiek , Nolen, Willem A. , Post, Robert M. , Altshuler, Lori L., Frye, Mark A. , Grunze, Heinz , Keck, Paul E., Suppes, Trisha, Beekman, Aartjan T.F. , Kupka, Ralph , van der Markt, Afra , Grunze, Heinz , McElroy, Susan L.

Mayo Clinic

Bipolar Disorders | November 17, 2018 | Volume: 21 | Issue: 3 | Pages: 228-234

10.1111/bdi.12727 | PMID 30447123 Get It

ObjectiveBipolar disorder has a wide range of clinical manifestations which may progress over time. The aim of this study was to test the applicability of a clinical staging model for bipolar disorder and to gain insight into the nature of the variables influencing progression through consecutive stages.MethodsUsing retrospectively reported longitudinal life chart data of 99 subjects from the Stanley Foundation Bipolar Network Naturalistic Follow‐up Study, the occurrence, duration and timely sequence of stages 2‐4 were determined per month. A multi‐state model was used to calculate progression rates and identify determinants of illness progression. Stages 0, 1 and several other variables were added to the multi‐state model to determine their influence on the progression rates.ResultsFive years after onset of BD (stage 2), 72% reached stage 3 (recurrent episodes) and 21% had reached stage 4 (continuous episodes), of whom 8% recovered back to stage 3. The progression from stage 2 to 3 was increased by a biphasic onset for both the depression‐mania and the mania‐depression course and by male sex.ConclusionsStaging is a useful model to determine illness progression in longitudinal life chart data. Variables influencing transition rates were successfully identified.
Trends in Patch Testing With the Mayo Clinic Standard Series, 2011–2015
Veverka, Kevin K. , Hall, Matthew R., Yiannias, James A. , Drage, Lisa A., Killian, Jill M. , Johnson, Janis S, Linehan, Diane L. Nordberg, Singh, Nidhi , Davis, Mark D. P. , Nordberg Linehan, Diane L, el‐Azhary, Rokea A. , Davis, Mark D.P.

Mayo Clinic

Dermatitis® | November 13, 2018 | Volume: 29 | Issue: 6 | Pages: 310-315

10.1097/der.0000000000000411 | PMID 30422883 Get It

Background Patch testing to a standard (baseline) series of allergens is the screening tool used to identify culprit allergens in patients with contact dermatitis. The allergens and concentrations used in a standard series are constantly evolving to be most relevant to the patients being patch tested. Objective The aim of this study was to analyze the 2011–2015 patch test results of the Mayo Clinic standard series. Methods We retrospectively reviewed patch test reactions of standard series allergens from 2011 through 2015 and compared these results with the 2011–2012 and 2013–2014 North American Contact Dermatitis Group (NACDG) reports. Conclusions Of 2582 patients included, 1566 (60.7%) had at least 1 positive reaction, and 516 (20.0%) had at least 1 irritant reaction. The 15 allergens with the highest reaction rates (from highest to lowest) were nickel sulfate hexahydrate, methylisothiazolinone, Myroxylon pereirae resin, neomycin sulfate, cobalt (II) chloride hexahydrate, benzalkonium chloride, fragrance mix I, potassium dichromate, bacitracin, methylchloroisothiazolinone/methylisothiazolinone, carba mix, formaldehyde, p -phenylenediamine, quaternium-15, and methyldibromo glutaronitrile. Twelve (80%) of these allergens were also in the top 15 of the most recent NACDG report; the 3 allergens not in the NACDG top 15 allergens were potassium dichromate, benzalkonium chloride, and methyldibromo glutaronitrile (the latter 2 allergens are not included in their series).
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Harrell, Maria I., Oza, Amit M. , Oaknin, Ana , Tinker, Anna V. , Helman, Elena , Radke, Marc R. , Say, Carmen , Vo, Lan-Thanh, Mann, Elaina, Isaacson, Jeffrey D., Maloney, Lara , O’Malley, David M. , Chambers, Setsuko K., Scott, Clare L. , Konecny, Gottfried E. , Giordano, Heidi, Harding, Thomas C., McNeish, Iain A. , Swisher, Elizabeth M. , Lin, Kevin K. , Kaufmann, Scott H , Brenton, James D , McNeish, Iain A , Swisher, Elizabeth M , Scott, Clare L , O'Malley, David M , Lin, Kevin , Ray-Coquard, Isabelle L. , Kaufmann, Scott H. , Coleman, Robert L. , Sun, James X. , Brenton, James D.

Mayo Clinic

Cancer Discovery | November 13, 2018 | Volume: 9 | Issue: 2 | Pages: 210-219

10.1158/2159-8290.cd-18-0715 | PMID 30425037 Get It

Abstract A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in BRCA-mutant cancers is the acquisition of BRCA reversion mutations that restore protein function. To estimate the prevalence of BRCA reversion mutations in high-grade ovarian carcinoma (HGOC), we performed targeted next-generation sequencing of circulating cell-free DNA (cfDNA) extracted from pretreatment and postprogression plasma in patients with deleterious germline or somatic BRCA mutations treated with the PARP inhibitor rucaparib. BRCA reversion mutations were identified in pretreatment cfDNA from 18% (2/11) of platinum-refractory and 13% (5/38) of platinum-resistant cancers, compared with 2% (1/48) of platinum-sensitive cancers (P = 0.049). Patients without BRCA reversion mutations detected in pretreatment cfDNA had significantly longer rucaparib progression-free survival than those with reversion mutations (median, 9.0 vs. 1.8 months; HR, 0.12; P < 0.0001). To study acquired resistance, we sequenced 78 postprogression cfDNA, identifying eight additional patients with BRCA reversion mutations not found in pretreatment cfDNA. Significance: BRCA reversion mutations are detected in cfDNA from platinum-resistant or platinum-refractory HGOC and are associated with decreased clinical benefit from rucaparib treatment. Sequencing of cfDNA can detect multiple BRCA reversion mutations, highlighting the ability to capture multiclonal heterogeneity. This article is highlighted in the In This Issue feature, p. 151
Revising Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project
Tavella, Gabriela , Berk, Michael , Grunze, Heinz , Deckersbach, Thilo , Dünner, David L., Amsterdam, Jay D., Ketter, Terence A. , Yatham, Lakshmi N. , Kessing, Lars Vedel , Bassett, Darryl, Fountoulakis, Kostas N, Duffy, Anne , Alda, Martin , Sharma, Verinder , Singh, Manpreet K. , Hájek, Tomáš , Boyce, Philip , Frey, Benício N. , Castle, David , Young, Allan H. , Vieta, Eduard , Swartz, Holly A. , Schaffer, Ayal , Murray, Greg , Bayes, Adam , Lam, Raymond W. , Post, Robert M, Ostacher, Michael J. , Lafer, Beny , Cleare, Anthony J. , O’Donovan, Claire , Ortiz, Abigail, Henry, Chantal , Kanba, Shigenobu, Rosenblat, Joshua D. , Parikh, Sagar V. , Bond, David J. , Goldberg, Joseph F. , Orum, Margo, Osser, David N. , Frye, Mark A. , Manicavasagar, Vijaya , Carlson, Gabrielle A. , Malhi, Gin S. , Fountoulakis, Konstantinos Ν. , Vieta, E , Grunze, Heinz , Bond, David J , Hajek, Tomas , Alda, Martin , Fountoulakis, Konstantinos N , Yatham, Lakshmi N , Young, Allan H , Cleare, Anthony J , Berk, Michael , Ortiz, Abigail , Parker, Gordon Barraclough , MacQUEEN, GLENDA M. , Sajatovic, Martha , Zimmerman, Mark A. , Fountoulakis, Kostas N, Calkin, Cynthia , Anand, Amit , Rybakowski, Janusz K , Bora, Emre , Post, Robert M, Burdick, Katherine E. , Grunebaum, Michael F. , Frangou, Sophia , McIntyre, Roger S. , Fagiolini, Andrea , Swartz, Holly A , Kessing, L V , Malhi, Gin S , Ostacher, Michael J

Mayo Clinic

Australian & New Zealand Journal of Psychiatry | October 31, 2018 | Volume: 52 | Issue: 12 | Pages: 1173-1182

10.1177/0004867418808382 | PMID 30378461 Get It

Objective: To derive new criteria sets for defining manic and hypomanic episodes (and thus for defining the bipolar I and II disorders), an international Task Force was assembled and termed AREDOC reflecting its role of Assessment, Revision and Evaluation of DSM and other Operational Criteria. This paper reports on the first phase of its deliberations and interim criteria recommendations. Method: The first stage of the process consisted of reviewing Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, and recent International Classification of Diseases criteria, identifying their limitations and generating modified criteria sets for further in-depth consideration. Task Force members responded to recommendations for modifying criteria and from these the most problematic issues were identified. Results: Principal issues focussed on by Task Force members were how best to differentiate mania and hypomania, how to judge ‘impairment’ (both in and of itself and allowing that functioning may sometimes improve during hypomanic episodes) and concern that rejecting some criteria (e.g. an imposed duration period) might risk false-positive diagnoses of the bipolar disorders. Conclusion: This first-stage report summarises the clinical opinions of international experts in the diagnosis and management of the bipolar disorders, allowing readers to contemplate diagnostic parameters that may influence their clinical decisions. The findings meaningfully inform subsequent Task Force stages (involving a further commentary stage followed by an empirical study) that are expected to generate improved symptom criteria for diagnosing the bipolar I and II disorders with greater precision and to clarify whether they differ dimensionally or categorically.
Clostridioides difficile uses amino acids associated with gut microbial dysbiosis in a subset of patients with diarrhea
Battaglioli, Eric , Hale, Vanessa L. , Jeraldo, Patricio , Ruiz-Mojica, Coral, Schmidt, Bradley A., Rekdal, Vayu Maini , Till, Lisa , Huq, Lutfi , Smits, Samuel A. , Moor, William, Jones‐Hall, Yava , Smyrk, Thomas C. , Khanna, Sahil , Pardi, Darrell S. , Grover, Madhusudan , Patel, Robin , Nelson, Heidi D , Sonnenburg, Justin L. , Farrugia, Gianrico , Kashyap, Purna , Battaglioli, Eric J , Jeraldo, Patricio R , Rekdal, Vayu M , Till, Lisa M , Huq, Lutfi , Smits, Samuel A , Moor, William J, Jones-Hall, Yava , Smyrk, Thomas , Grover, Madhusudan , Chia, Nicholas , Sonnenburg, Justin L , Farrugia, Gianrico , Kashyap, Purna C , Patel, Robin , Chen, Jun , Ruiz-Mojica, Coral A. , Chia, Nicholas

Mayo Clinic

Science Translational Medicine | October 24, 2018 | Volume: 10 | Issue: 464 | Pages: No page available

10.1126/scitranslmed.aam7019 | PMID 30355801 Get It

Increased amino acids in the dysbiotic gut influences susceptibility to Clostridioides difficile infection in mice and humans.
Trends in Chronic Liver Disease-Related Hospitalizations: A Population-Based Study
Hall, Lauren , Hagan, Michael , Sharma, Sushma, Yeramaneni, Samrat , Trotter, James F. , Talwalkar, Jayant A., Kanwal, Fasiha , Talwalkar, Jayant, Asrani, Sumeet K. , Hall, Lauren

Mayo Clinic

American Journal of Gastroenterology | October 17, 2018 | Volume: 114 | Issue: 1 | Pages: 98-106

10.1038/s41395-018-0365-4 | PMID 30333543 Get It

OBJECTIVES: In a population-based study, we examined time trends in chronic liver disease (CLD)-related hospitalizations in a large and diverse metroplex. METHODS: We examined all CLD-related inpatient encounters (2000–2015) in Dallas–Fort Worth (DFW) using data from the DFW council collaborative that captures claims data from 97% of all hospitalizations in DFW (10.7 million regional patients). RESULTS: There were 83,539 CLD-related hospitalizations in 48,580 unique patients across 84 hospitals. The age and gender standardized annual rate of CLD-related hospitalization increased from 48.9 per 100,000 in 2000 to 125.7 per 100,000 in 2014. Mean age at hospitalization increased from 54.0 (14.1) to 58.5 (13.5) years; the proportion of CLD patients above 65 years increased from 24.2% to 33.1%. HCV-related hospitalizations plateaued, whereas an increase was seen in hospitalizations related to alcohol (9.1 to 22.7 per 100,000) or fatty liver (1.4 per 100,000 to 19.5 per 100,000). The prevalence of medical comorbidities increased for CLD patients: coronary artery disease (4.8% to 14.3%), obesity (2.8% to 14.6%), chronic kidney disease (2.8% to 18.2%), and diabetes (18.0% to 33.2%). Overall hospitalizations with traditional complications of portal hypertension (ascites, varices, and peritonitis) remained stable over time. However, hospitalization with complications related to infection increased from 54.7% to 66.4%, and renal failure increased by sevenfold (2.7% to 19.5%). CONCLUSIONS: CLD-related hospitalizations have increased twofold over the last decade. Hospitalized CLD patients are older and sicker with multiple chronic conditions. Traditional complications of portal hypertension have been superseded by infection and renal failure, warranting a need to redefine what it means to have decompensated CLD.
ADVL1522: A phase 2 study of IMGN901 (lorvotuzumab mertansine; IND# 126953, NSC# 783609) in children with relapsed or refractory Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor (MPNST), and sy
Kudgus, Rachel A. , Schoon, Renee A., McGovern, Renee M., Cajaiba, Mariana M. , Barkauskas, Donald A. , Dome, Jeffrey S. , Fox, Elizabeth , Weigel, Brenda J. , Geller, James I. , Pressey, Joseph G. , Smith, Malcolm A. , Reid, Joel M. , Hall, David

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 10537-10537

10.1200/jco.2017.35.15_suppl.10537 Get It

10537 Background: Lorvotuzumab mertansine (IMGN901; LM) is an antibody-drug conjugate, linking anti-mitotic agent (DM1) to an anti-CD56 antibody. Preclinical data show effects in Wilms tumor (WT), rhabdomyosarcoma (RMS), and neuroblastoma (NBL). Synovial sarcoma (SS), MPNST and pleuropulmonary blastoma (PPB) also express CD56. A phase 2 trial assessing the efficacy and tolerability of LM administered at the adult recommended phase 2 dose (RP2D) was conducted in children with relapsed tumors. Methods: LM (110 mg/m2/dose) was administered IV on days (d) 1 and 8 of 21 d cycles, with dexamethasone pre-medication. The tolerability of LM was assessed in 6 patients prior to trial activation group-wide. Dose limiting toxicity (DLT) was assessed using CTCAE. Response was assessed by RECIST. Pharmacokinetics (PK) were obtained during cycle 1. Peripheral blood CD56-positive cells were measured d1 and d8 pre-dose. Tumor CD56 expression by immunohistochemistry in archival tissue was scored (0-3+). Results: Sixty-two patients were enrolled. The median (range) age was 14.3 y (2.8–29.9); 35 were male. Diagnoses included WT (17), RMS (17), NBL (12), SS (10), MPNST (5) and PPB (1). One patient was ineligible due to lack of measurable disease. Of 61 eligible patients, 47 were evaluable for toxicity, 50 for response, 50 for tumor CD56 expression; and 18 consented to optional PK. Five patients experienced 9 DLTs: hyperglycemia (1), colonic fistula (1) with perforation (1), nausea (1) with vomiting (1), increased ALT (2 in cycle 1; 1 in cycle 2 with increased AST (1)). Non-dose limiting toxicities (Grade ≥3) attributed to LM included lymphopenia, anemia, vomiting, dehydration, hypokalemia, hyperuricemia, hypophosphatemia. Mean DM1 Cmax, t1/2 and AUC0-∞values were 922 ng/ml, 33 h and 27400 ng/ml*h, respectively. Tumor CD56 expression was 0 (8%), 1+(4%), 2+(12%), 3+(76%). LM and CD56 antibody PK, and response, will be reported. Conclusions: LM (110 mg/m2) is tolerated in children at the adult RP2D. Clinical trial information: NCT 02452554.
Impact of early FDG-PET directed intervention on preoperative therapy for locally advanced gastric cancer: A Cooperative Group random assignment phase II study (Alliance A021302) Impac.
Strong, Vivian E. , Strasser, Jon, Ilson, David H. , Kleinberg, Lawrence , Iqbal, Syma , Wuthrick, Evan , Levasseur, Alexandra, Shah, Manish A , Shi, Qian , Strasser, Jon, Hall, Nathan C. , Meyerhardt, Jeffrey A. , O’Reilly, Eileen M.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: TPS4135-TPS4135

10.1200/jco.2017.35.15_suppl.tps4135 Get It

TPS4135 Background: Gastric cancer is a prevalent and morbid illness for which new treatment strategies are needed. Peri-operative therapy is a standard approach that is associated with only a 15% improvement in overall survival. Early FDG-PET scanning, performed prior to cycle 2, can distinguish patients (pts) responding to chemotherapy from those who are not. FDG-PET non-responding pts have poorer survival. This study addresses the question of salvage therapy in pts who are PET non-responders. Specifically, does salvage chemotherapy with docetaxel /irinotecan improve pt survival in FDG-PET-nonresponding pts with locally advanced gastric cancer. Methods: This is a multicenter, cooperative group, NCI supported, randomized phase II study of salvage chemotherapy + surgery versus surgery and post-operative chemoradiotherapy in pts who are FDG-PET non-responders (defined as a decrease in SUVmaxof the primary tumor of less than 35%). A total of 176 pts with locally advanced, resectable gastric cancer who were FDG-PET non-responders to cycle 1 of platinum/capecitabine based chemotherapy will be randomized in a 1:1 manner to receive either (Arm A) surgery followed by fluoropyrimidine-sensitized radiotherapy (4500 cGy), or (Arm B) salvage chemotherapy with docetaxel / irinotecan (DI) for 2 cycles followed by standard resection and 3 cycles DI post-operatively. DI is administered as D 30 mg/m2, I 50 mg/m2 given on D1, D8 of a 21 day cycle. 416 pts will be screened to yield 162 non-responders (81 FDG-PET non-responders per treatment group). With expected 120 events, the study will have 80% power to detect a hazard ratio of 0.625 for improved survival at the one-sided significant level of 0.15. Pts will be required to provide tissue at the time of resection, as well as whole blood prior to resection for correlative studies associated with platinum sensitivity, FDG avidity, and prognostic markers. This study is available through all cooperative groups (SWOG, ACRIN/ECOG, Alliance, and NRG) and the National Clinical Trials Network. Enrollment began in November 2015. Support: U10CA180821, U10CA180882; Clinical Trial Information: NCT02485834 .
Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO1 to predict outcomes to anti-PD-1 in metastatic melanoma (MM).
Johnson, Douglas B. , Bordeaux, Jennifer , Vaupel, Christine, Conry, Robert M. , Gaughan, Elizabeth , Balko, Justin M. , Smithy, James W. , Witte, John S. , McKee, Svetlana B., Dominiak, Nicole , Dabbas, Bashar , Hall, Jeff , Dakappagari, Naveen, Leadership, Navigate BioPharma, Wrangle, John M , Kim, Ju‐Young , Rimm, David L. , Ho, Thai H. , Joseph, Richard W. , Daud, Adil , Dimou, Anastasios , Leadership, Navigate BioPharma

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 9517-9517

10.1200/jco.2017.35.15_suppl.9517 Get It

9517 Background: Although PD-1/L1 axis directed therapies induce durable responses in some mm patients (pts), biomarkers of response remain elusive. We hypothesized that quantifying key immune suppression mechanisms within the tumor microenvironment would provide superior predictors of response to anti-PD-1 compared with single marker assessment. Methods: Pre-treatment tumor biopsies from 124 mm pts treated with anti-PD-1 at 7 academic centers were fluorescently stained with multiple immune markers in discovery (n = 24) and validation (n = 100) cohorts. Selected biomarker signatures, PD-1/PD-L1 interaction score (proportion of PD-1+ cells co-localized with PD-L1) and IDO1/HLA-DR co-expression were evaluated for anti-PD-1 treatment response and survival. Slides were imaged using Vectra; biomarker positive cells and their co-localization were objectively quantified in pathologist-selected regions using novel Automated Quantitative Analysis (AQUA) algorithms. Results: In the discovery cohort, high levels of PD-1/PD-L1 interaction score and/or IDO1/HLA-DR coexpression was strongly positively associated with response to anti-PD-1 (p = 0.0005). In contrast, other individual biomarkers (PD-1, PD-L1, CD8) were not associated with response or survival (p > 0.10). This finding was replicated in the validation cohort: pts with high PD-1/PD-L1 and/or IDO1/HLA-DR were more likely to respond to treatment (p = 0.009). These pts also experienced a three-fold increase in progression free survival (hazards ratio (HR) = 0.33; p = 0.003) and overall survival (HR = 0.34; p = 0.004). Multivariate analyses revealed that these findings were independent of BRAF mutation, stage, LDH and prior therapy. In the combined cohort (n = 124), 80% of responding pts had higher levels of PD-1/PD-L1 interaction scores and/or IDO1/HLA-DR. In contrast, PD-L1 expression alone (≥1% or ≥50%) was not predictive of PFS or OS (p > 0.1). Conclusions: This novel multiplexed method profiling key tumor-immune suppression pathways identified mm pts likely to respond to anti-PD-1 therapy. This method could help stratify patients for PD-1 monotherapy and be useful in guiding future clinical trials.
Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.
Twohy, Erin , Meyers, Michael O. , Boffa, Daniel J., Mitchell, Kisha A. , Ilson, David H. , Goodman, Karyn A. , Hall, Nathan C. , Bekaii‐Saab, Tanios , Ou, Fang‐Shu , Perry, Kyle A. , Frankel, Wendy L. , Venook, Alan P. , O’Reilly, Eileen M.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4012-4012

10.1200/jco.2018.36.15_suppl.4012 Get It